Literature DB >> 12502829

Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.

Sandra Kao1, Hirofumi Akari, Mohammad A Khan, Markus Dettenhofer, Xiao-Fang Yu, Klaus Strebel.   

Abstract

Packaging of the human immunodeficiency virus type 1 Vif protein into virus particles is mediated through an interaction with viral genomic RNA and results in the association of Vif with the nucleoprotein complex. Despite the specificity of this process, calculations of the amount of Vif packaged have produced vastly different results. Here, we compared the efficiency of packaging of Vif into virions derived from acutely and chronically infected H9 cells. We found that Vif was efficiently packaged into virions from acutely infected cells (60 to 100 copies per virion), while packaging into virions from chronically infected H9 cells was near the limit of detection (four to six copies of Vif per virion). Superinfection by an exogenous Vif-defective virus did not rescue packaging of endogenous Vif expressed in the chronically infected culture. In contrast, exogenous Vif expressed by superinfection of wild-type virus was readily packaged (30 to 40 copies per virion). Biochemical analyses suggest that the differences in the relative packaging efficiencies were not due to gross differences in the steady-state distribution of Vif in chronically or acutely infected cells but are likely due to differences in the relative rates of de novo synthesis of Vif. Despite its low packaging efficiency, endogenously expressed Vif was sufficient to direct the production of viruses with almost wild-type infectivity. The results from our study provide novel insights into the biochemical properties of Vif and offer an explanation for the reported differences regarding Vif packaging.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502829      PMCID: PMC140813          DOI: 10.1128/jvi.77.2.1131-1140.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.

Authors:  A M Borman; C Quillent; P Charneau; C Dauguet; F Clavel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

2.  The redox state of cysteines in human immunodeficiency virus type 1 Vif in infected cells and in virions.

Authors:  P Sova; W Chao; D J Volsky
Journal:  Biochem Biophys Res Commun       Date:  1997-11-17       Impact factor: 3.575

3.  Role of vif during packing of the core of HIV-1.

Authors:  S Höglund; A Ohagen; K Lawrence; D Gabuzda
Journal:  Virology       Date:  1994-06       Impact factor: 3.616

4.  A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes.

Authors:  J K Yee; A Miyanohara; P LaPorte; K Bouic; J C Burns; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

5.  Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes.

Authors:  J H Simon; T E Southerling; J C Peterson; B E Meyer; M H Malim
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  Subcellular localization of the Vif protein of human immunodeficiency virus type 1.

Authors:  J Goncalves; P Jallepalli; D H Gabuzda
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2.

Authors:  F H Michaels; N Hattori; R C Gallo; G Franchini
Journal:  AIDS Res Hum Retroviruses       Date:  1993-10       Impact factor: 2.205

8.  Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency.

Authors:  S T Butera; B D Roberts; L Lam; T Hodge; T M Folks
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.

Authors:  M Courcoul; C Patience; F Rey; D Blanc; A Harmache; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants.

Authors:  T R Reddy; G Kraus; O Yamada; D J Looney; M Suhasini; F Wong-Staal
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  34 in total

1.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

Review 2.  Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system.

Authors:  Elana S Ehrlich; Xiao-Fang Yu
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

3.  Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.

Authors:  Rajesh Thippeshappa; Patricia Polacino; Monica T Yu Kimata; Edward B Siwak; David Anderson; Weiming Wang; Laura Sherwood; Reetakshi Arora; Michael Wen; Paul Zhou; Shiu-Lok Hu; Jason T Kimata
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 4.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

5.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Authors:  Tao Zuo; Donglai Liu; Wei Lv; Xiaodan Wang; Jiawen Wang; Mingyu Lv; Wenlin Huang; Jiaxin Wu; Haihong Zhang; Hongwei Jin; Liangren Zhang; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  HIV-1 Vif and APOBEC3G: multiple roads to one goal.

Authors:  Joao Goncalves; Mariana Santa-Marta
Journal:  Retrovirology       Date:  2004-09-21       Impact factor: 4.602

7.  Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.

Authors:  Sandra Kao; Ritu Goila-Gaur; Eri Miyagi; Mohammad A Khan; Sandrine Opi; Hiroaki Takeuchi; Klaus Strebel
Journal:  Virology       Date:  2007-09-06       Impact factor: 3.616

8.  Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells.

Authors:  Naoya Uchida; Kareem N Washington; Jun Hayakawa; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

9.  Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.

Authors:  Dibyakanti Mandal; Colin M Exline; Zehua Feng; C Martin Stoltzfus
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

10.  HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation.

Authors:  Gaëlle Mercenne; Serena Bernacchi; Delphine Richer; Guillaume Bec; Simon Henriet; Jean-Christophe Paillart; Roland Marquet
Journal:  Nucleic Acids Res       Date:  2009-11-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.